Repatha 140 mg injection

Repatha (evolocumab) is a prescription biological medication used to reduce low-density lipoprotein (LDL) cholesterol. It was developed by Amgen, a pioneer in the biotechnology industry. The product shown is a pre-filled SureClick autoinjector containing 140 mg of the solution.

Manufacturing of biological products like Repatha is complex and typically involves multiple global sites across the United States, Ireland, and Puerto Rico, where Amgen maintains significant biotechnology manufacturing facilities. Ownership of the brand remains with Amgen Inc., an American multinational company that is one of the world's largest independent biotechnology firms. In Germany and other European markets, it is distributed through Amgen's local subsidiaries.